Boule Diagnostics

Interim report
Q1 2024

Financial Highlights

NET SALES, SEK million
147.8
GROSS MARGIN
46.2
%
OPERATING PROFIT, SEK million
15.4
CASH FLOW FROM OPERATING ACTIVITIES, SEK million
12.5
Image (1)

Strong operating profit improvement

Despite challenging market conditions with uncertainties and geopolitical disturbance in some of our key markets, we had a good start to the year. Sales growth was 3.3% with organic growth of 5.4%. Western Europe and Asia delivered strong growth, US and Middle East was stable, while Africa and Latin America declined.

Gross margin was flat compared to last year 46.2% (46.2), with lower margins on continued deliveries to the strategic customer in India.

Operating expenses were in line with last year when including a one-time redundancy cost of SEK 3.7 million related to the CEO change. Excluding the one-time cost, the operating expenses decreased by 7%. 

Operating margin improved by 2 percentage points to 10.5% (8.5). Excluding the one-time cost the operating margin improved by 4.4 percentage points to 12.9% and operating profit increased with 58%. Cash flow from operating activities improved to SEK 12 million (-9). Liquidity strengthened in the quarter and cash and cash equivalents were SEK 41 million. Cash and available credit facilities amounted to SEK 100 million.

Net sales by region

Net sales by product

Near-patient diagnostics

Complete Blood Count (CBC) is the most common test for in vitro diagnostics. The decentralized and patient-related hematology segment has an estimated market value of just over SEK 8 billion, while the corresponding segment for the veterinary market is valued at approximately SEK 2.6 billion

Map En

200
+

Distributors in 100 countries

SEK
8
BILLION

Addressable market Human

150
MILLION

Tests per year

ABOUT BOULE DIAGNOSTICS

Boule Diagnostics AB is a global diagnostics company specializing in near-patient, decentralized blood diagnostics and one of the few companies in the global diagnostics market that conducts its own development, manufacturing and marketing of instruments and consumables for blood diagnostics. The Company primarily serves hospitals, clinics, laboratories and other diagnostics companies.